Drug Profile
Influenza A virus vaccine H5N1 - GSK
Alternative Names: (Pre)-pandemic vaccine against H5N1 inactivated split - monovalent (Dresden) - GSK; (Pre)-pandemic vaccine against H5N1 inactivated split - monovalent (Quebec) - GSK; Adjupanrix; GSK 2590066A; GSK 2592984A; GSK1119711A; GSK1557484A; GSK1562902A; H5N1 (pre-)pandemic influenza virus vaccine - GSK; H5N1 Clade 1 strain (pre-)pandemic influenza vaccine - GSK; Pandemic vaccine against H5N1 inactivated split - monovalent (Quebec) - GSK; Pre-pandemic influenza vaccine - GSK; Prepandrix; Pumarix; Q-Pan H5N1; Split virion, inactivated, adjuvanted (pre-)pandemic H5N1 influenza vaccine - GSKLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK; Japan Vaccine
- Class Influenza A virus H5N1 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Influenza A virus H5N1 subtype
Most Recent Events
- 30 Jul 2019 Influenza A virus vaccine H5N1 is not yet available for Influenza A virus H5N1 subtype (Prevention) in Canada, Iceland, Liechtenstein, Norway, Switzerland, USA (IM)
- 13 Feb 2018 GlaxoSmithKline completes a phase II trial in Influenza-A virus H5N1 subtype (Prevention, In infants, In children) in Taiwan, Thailand (IM) (NCT02719743)
- 01 Jul 2016 Phase-II clinical trials in Influenza-A virus H5N1 subtype (Prevention, In infants, In children) in Taiwan, Thailand (IM) (NCT02719743)